Pharmacology & Pharmacy

Volume 7, Issue 8 (August 2016)

ISSN Print: 2157-9423   ISSN Online: 2157-9431

Google-based Impact Factor: 0.67  Citations  

S(+)-Flurbiprofen Shows Potent PGE2 Inhibitory Activity in Inflammatory Cells, Superior Cell Transport Activity and Skin Permeability

HTML  XML Download Download as PDF (Size: 1091KB)  PP. 305-312  
DOI: 10.4236/pp.2016.78037    2,015 Downloads   3,675 Views  Citations

ABSTRACT

We developed a novel topical non-steroidal anti-inflammatory drug (NSAID)patch, S(+)-flurbiprofen plaster, (SFPP), containing S(+)-flurbiprofen (SFP), an enantiomer of flurbiprofen (FP). In a previous study conducted in an animal model, we showed good skin absorption and potent analgesic efficacy of SFPP. In this study, to examine the superior features, as an NSAID patch, of SFP as compared to FP and R(-)-flurbiprofen (RFP), we tested the stereospecificity of SFP actions on Prostaglandin E2 (PGE2) inhibition in rat inflammatory leukocytes and in the binding activity of the drug to cells, and also the in vitro skin permeability of the drug in the Yucatan micropig (YMP). SFP showed potent inhibitory activity on PGE2 production from peritoneal leukocytes stimulated with a bacterial suspension, as compared to RFP and FP. The half maximal (50%) inhibitory concentration (IC50) values were 14 nM for SFP, 52 nM for FP, and 17,000 nM for RFP. In the cell binding study, significant and rapid increase of SFP binding to polymorphonuclear leucocytes (PMNs) was observed at 5 min after incubation, eventually reaching a steady state. SFP showed significantly higher binding activity for the inflammatory leucocytes as compared to RFP, suggesting its superior transfer potency. The skin permeability profile of SFP, RFP and FP in the YMP model showed that the rank order of the cumulative amount of permeated compounds in the skin was SFP > RFP > FP. The steady-state permeation rate (Flux) of SFP was significantly higher than that of FP (4.89 and 1.55 mg/cm2/h, respectively, p = 0.0068), indicating the remarkably superior skin permeability of SFP. SFP exerted potent inhibitory activity on PGE2 production and superior binding activity to the PMNs and skin permeability, as compared to FP and RFP. These results suggest that SFP possesses favorable characteristics for use as an active ingredient in the NSAID patch.

Share and Cite:

Toda, Y. , Sugimoto, M. , Endo, H. , Kamezawa, M. , Yamada, I. , Kawabata, S. , Kaku, S. , Otsuka, N. and Matsumoto, H. (2016) S(+)-Flurbiprofen Shows Potent PGE2 Inhibitory Activity in Inflammatory Cells, Superior Cell Transport Activity and Skin Permeability. Pharmacology & Pharmacy, 7, 305-312. doi: 10.4236/pp.2016.78037.

Cited by

[1] Engineering Styrene Oxide Isomerase Towards Enhanced Chemoenzymatic Synthesis of (S)‐Flurbiprofen
Advanced Synthesis & …, 2024
[2] Efficacy and safety of S‐flurbiprofen plaster in knee osteoarthritis patients: A 2‐week randomized controlled Phase III clinical trial compared to diclofenac gel
International Journal of …, 2022
[3] 新規 NSAID エスフルルビプロフェンテープ剤の変形性関節症を対象とした臨床開発研究-経皮吸収向上がもたらす効果と安全性の検討
Dissertation, 2019
[4] 変形性膝関節症に対するエスフルルビプロフェンテープの有用性検討
2019
[5] Analgesic effect of S (+)-flurbiprofen plaster in a rat model of knee arthritis: analysis of gait and synovial fluid prostaglandin E2 levels
2018
[6] Analgesic effect of S (+)‐flurbiprofen plaster in a rat model of knee arthritis: analysis of gait and synovial fluid prostaglandin E2 levels
Journal of Pharmacy and Pharmacology, 2018
[7] 新規 NSAIDs エスフルルビプロフェン貼付剤 (ロコア® テープ) の薬理学的特長と臨床試験成績
日本薬理学雑誌, 2018
[8] 変形性膝関節症患者に対するヒアルロン酸注射剤と外用 NSAIDs テープ (S (+)-flurbiprofen) との有効性の比較検討
中部日本整形外科災害外科学会雑誌, 2018
[9] 変形性関節症 (変形性脊椎症を含む) に対する新規非ステロイド性抗炎症薬エスフルルビプロフェンプラスター剤の長期投与時の有効性および安全性について
2017
[10] A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients
Clinical and Experimental Nephrology, 2017

Copyright © 2025 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.